Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 137

Sort by

Sort Order Select

Journal Articles

Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 3431.

https://doi.org/10.1182/blood-2025-3431

Published: 2025

Journal Articles

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Blood (2025) 146 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2025-3415

Published: 2025

Journal Articles

A dynamic comprehensive geriatric assessment demonstrates improvement in patient fitness after induction and predicts survival and treatment tolerability among older adults with newly diagnosed acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 5153.

https://doi.org/10.1182/blood-2025-5153

Published: 2025

Journal Articles

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

Ted Getz, Kelly Pugh, Andrew Brunner, Jan Philipp Bewersdorf, Amy DeZern, Tariq Kewan, Uma Borate, Uwe Platzbecker, Mikkael Sekeres, Andrew Wei, Shahram Kordasti, Rena Buckstein, Gail Roboz, Michael Savona, Sanam Loghavi, Robert Hasserjian, Pierre Fenaux, David Sallman, Christopher Hourigan, Matteo Della Porta, Stephen Nimer, Richard Little, Valeria Santini, Fabio Efficace, Justin Taylor, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami Komrokji, Elizabeth Griffiths, Peter Greenberg, Mina Xu, Zhuoer Xie, Rafael Bejar, Guillermo Sanz, Mrinal Patnaik, Maria E. Figueroa, Hetty Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval Daver, Jane Churpek, Ravi Majeti, John Bennett, Alan List, Adrian Mosquera Orgueira, Klaus Metzeler, Francesc Sole, Lisa Pleyer, Arjan Van de Loosdrecht, Thomas Cluzeau, David Steensma, Ghulam Mufti, Lionel Ades, Luca Lanino, Yazan Madanat, Anne Sophie Kubasch, Marie Sebert, R. Coleman Lindsley, Katharina S. Götze, Carmelo Gurnari, Yasushi Miyazaki, Aref Al-Kali, Abdulraheem Yacoub, Bing Li, Ioannis Kotsianidis, Maximilian Stahl, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2025-3852

Published: 2025

Journal Articles

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Blood (2025) 146 (Supplement 1): 2838.

https://doi.org/10.1182/blood-2025-2838

Published: 2025

Journal Articles

Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms

Anand Patel, Michael Drazer, Theodore Karrison, Lorraine Pelosof, Steven Gore, Richard Little, Alexey Danilov, Olatoyosi Odenike

Blood (2025) 146 (Supplement 1): 3827.

https://doi.org/10.1182/blood-2025-3827

Published: 2025

Journal Articles

Ruxolitinib and cardiovascular outcomes among patients with myelofibrosis

Orly Leiva, Steven Soo, Olivia Liu, Victor You, Andrew Palmer, Justin Kahla, Yasmeen Murtaza, Olatoyosi Odenike, Anand Patel, Jeanne DeCara, Michelle Lee, Chi-Joan How, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 3796.

https://doi.org/10.1182/blood-2025-3796

Published: 2025

Journal Articles

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study

Alice Mims, Lai Wei, Eric McLaughlin, Jayanshu Jain, Joshua Zeidner, Olatoyosi Odenike, Sangeetha Venugopal, James Blachly, Vu Duong, Anand Patel, Eric Eisenmann, Shelley Orwick, Daelynn Buelow, Gregory Behbehani, Richard Little, Steven Gore, Sharyn Baker

Blood (2025) 146 (Supplement 1): 5206.

https://doi.org/10.1182/blood-2025-5206

Published: 2025

Journal Articles

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Blood (2025) 146 (Supplement 1): 441.

https://doi.org/10.1182/blood-2025-441

Published: 2025

Journal Articles

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Blood (2025) 146 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2025-5279

Published: 2025

Journal Articles

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 790.

https://doi.org/10.1182/blood-2025-790

Published: 2025

Journal Articles

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

Anand Patel, Theodore Karrison, Emily Dworkin, Rafael Madero-Marroquin, Austin Wesevich, Gregory Roloff, Caner Saygin, Mariam Nawas, Michael Drazer, Adam Duvall, Satyajit Kosuri, Michael Thirman, Wendy Stock, Richard Larson, Olatoyosi Odenike

Blood (2025) 146 (Supplement 1): 5608.

https://doi.org/10.1182/blood-2025-5608

Published: 2025

Journal Articles

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Blood (2025) 146 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2025-5136

Published: 2025

Journal Articles

Pulmonary hypertension on right heart catheterization is associated with worse progression-free survival in patients with myeloproliferative neoplasms

Orly Leiva, Olivia Liu, Victor You, Steven Soo, Justin Kahla, Yasmeen Murtaza, Andrew Palmer, Anand Patel, Olatoyosi Odenike, Michelle Lee, Chi-Joan How, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 5583.

https://doi.org/10.1182/blood-2025-5583

Published: 2025

Journal Articles

Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms

Orly Leiva, Steven Soo, Olivia Liu, Victor You, Andrew Palmer, Justin Kahla, Yasmeen Murtaza, Olatoyosi Odenike, Anand Patel, Jeanne DeCara, Max Petersen, Patrycja Dubielecka, Michelle Lee, Chi-Joan How, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 5571.

https://doi.org/10.1182/blood-2025-5571

Published: 2025

Journal Articles

Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study

Hannah Johnston, Abigail Sneider, Tuula Pera, Rafael Madero-Marroquin, Austin Wesevich, Gregory Roloff, Mariam Nawas, Anand Patel, Michael Drazer, Adam Duvall, Satyajit Kosuri, Michael Thirman, Olatoyosi Odenike, Richard Larson, Caner Saygin, Wendy Stock, Christopher Daugherty

Blood (2025) 146 (Supplement 1): 6382.

https://doi.org/10.1182/blood-2025-6382

Published: 2025

Journal Articles

Decreased serum total cholesterol is associated with worse outcomes among patients with myeloproliferative neoplasms

Orly Leiva, Steven Soo, Olivia Liu, Victor You, Andrew Palmer, Justin Kahla, Yasmeen Murtaza, Olatoyosi Odenike, Anand Patel, Jeanne DeCara, Michelle Lee, Chi-Joan How, Max Petersen, Patrycja Dubielecka, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 2020.

https://doi.org/10.1182/blood-2025-2020

Published: 2025

Journal Articles

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Blood (2025) 146 (Supplement 1): 995.

https://doi.org/10.1182/blood-2025-995

Published: 2025

Journal Articles

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Blood (2025) 146 (Supplement 1): 992.

https://doi.org/10.1182/blood-2025-992

Published: 2025

Journal Articles

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Jan Philipp Bewersdorf, Maximilian Stahl, Amy E. DeZern, Uwe Platzbecker, Mikkael A. Sekeres, Andrew H. Wei, Rena J. Buckstein, Gail J. Roboz, Michael R. Savona, Sanam Loghavi, Robert P. Hasserjian, Pierre Fenaux, David A. Sallman, Christopher S. Hourigan, Matteo Giovanni Della Porta, Stephen Nimer, Richard F. Little, Valeria Santini, Fabio Efficace, Justin Taylor, Guillermo Garcia-Manero, Olatoyosi Odenike, Tae Kon Kim, Stephanie Halene, Rami S. Komrokji, Elizabeth A. Griffiths, Peter L. Greenberg, Mina L. Xu, Zhuoer Xie, Rafael Bejar, Guillermo F. Sanz, Mrinal M. Patnaik, Maria Figueroa, Hetty E. Carraway, Omar Abdel-Wahab, Daniel Starczynowski, Eric Padron, Jacqueline Boultwood, Steven Gore, Naval G. Daver, Jane E. Churpek, Ravindra Majeti, John M. Bennett, Alan F. List, Andrew M. Brunner, Amer M. Zeidan

Blood (2025) 145 (13): 1369–1381.

https://doi.org/10.1182/blood.2023023717

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML)

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

A dynamic comprehensive geriatric assessment demonstrates improvement in patient fitness after induction and predicts survival and treatment tolerability among older adults with newly diagnosed acute myeloid leukemia

Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts

The impact of environmental air exposues on disease characteristics and outcomes in a cohort of patients with myelofibrosis

Trial in progress - a randomized study of ASTX727 with or without Iadademstat in accelerated/blast-phase myeloproliferative neoplasms

Ruxolitinib and cardiovascular outcomes among patients with myelofibrosis

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Low-dose oral decitabine and cedazuridine among patients with low-risk myelodysplastic syndromes

Trial in progress – a phase 1b trial of ivosidenib combined with ruxolitinib in IDH1-mutated advanced myeloproliferative neoplasms

Trial in progress: A Phase I/II study to investigate the combination of LP-118, ponatinib, vincristine and dexamethasone (LPVd regimen) in relapsed/refractory T-ALL/lbl

Pulmonary hypertension on right heart catheterization is associated with worse progression-free survival in patients with myeloproliferative neoplasms

Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms

Spiritual wellness and quality-of-life in adult patients with newly diagnosed acute leukemia receiving initial therapy: Patient-reported outcomes (PROs) from a prospective observational study

Decreased serum total cholesterol is associated with worse outcomes among patients with myeloproliferative neoplasms

RAS mutations negate the favorable impact of NPM1 in older patients with newly diagnosed Acute Myeloid Leukemia treated with ven/HMA

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only